Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Yucai Wang

Yucai Wang

MD, PhD
Mayo Clinic
Challenges that remain in treating older patients with MCL & the value of tailored approaches 2:31
Challenges that remain in treating older patients with MCL & the value of tailored approaches
Yucai Wang • 18 Jun 2025
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL 3:23
A Phase I/II trial of orelabrutinib, a covalent BTK inhibitor, in R/R MCL
Yucai Wang • 18 Jun 2025
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL 4:07
Rapid ramp-up dosing of bispecific antibodies targeting CD3 and CD20 for R/R LBCL
Yucai Wang • 18 Jun 2025
Selecting between covalent and non-covalent BTK inhibitors for patients with MCL 1:29
Selecting between covalent and non-covalent BTK inhibitors for patients with MCL
Yucai Wang • 18 Jun 2025
The impact of BTKis on the treatment landscape for R/R MCL 2:41
The impact of BTKis on the treatment landscape for R/R MCL
Yucai Wang • 8 Dec 2024
Strategies to overcome resistance to BTKis in R/R MCL 2:38
Strategies to overcome resistance to BTKis in R/R MCL
Yucai Wang • 8 Dec 2024
Association of biological sex, race & ethnicity with clinical characteristics and survival in MCL 2:51
Association of biological sex, race & ethnicity with clinical characteristics and survival in MCL
Yucai Wang • 8 Dec 2024
Phase I/Ib study of parsaclisib plus standard immunochemotherapy for newly diagnosed DLBCL 4:39
Phase I/Ib study of parsaclisib plus standard immunochemotherapy for newly diagnosed DLBCL
Yucai Wang • 8 Dec 2024
The challenges with monitoring patients with lymphoma for cardiotoxicity 2:22
The challenges with monitoring patients with lymphoma for cardiotoxicity
Yucai Wang • 2 Jun 2024
Is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for MCL? 3:10
Is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for MCL?
Yucai Wang • 3 Jun 2024
A Phase II trial of pembrolizumab for Richter’s transformation of CLL 2:46
A Phase II trial of pembrolizumab for Richter’s transformation of CLL
Yucai Wang • 2 Jun 2024
Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
MIRACLE study: using an MRD-guided strategy to direct treatment duration in previously untreated CLL 3:26
MIRACLE study: using an MRD-guided strategy to direct treatment duration in previously untreated CLL
Yucai Wang • 8 Oct 2023
Results from the US Lymphoma CAR-T consortium on brexu-cel for R/R MCL in SoC practice 2:40
Results from the US Lymphoma CAR-T consortium on brexu-cel for R/R MCL in SoC practice
Yucai Wang • 8 Oct 2023
Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
The content of VJHemOnc is intended for healthcare professionals